Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis

被引:49
作者
Luzzatto, G
Bertoli, M
Cella, G
Fabris, F
Zaia, B
Girolami, A
机构
[1] Padua Univ Hosp, Dept Med 2, Padua, Italy
[2] Padua Univ Hosp, Div Nephrol & Dialysis, Padua, Italy
关键词
platelet count; thrombocytopenia; heparin; protease inhibitors; chronic kidney failure; dialysis;
D O I
10.1016/S0049-3848(97)00301-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We studied 50 chronic dialysis patients with end-stage renal disease. Mean platelet count was within normal limits. An inverse linear correlation was observed between pre-dialysis platelet count and serum creatinine (r=0.304, p=0.038). Dialysis caused a decrease in platelet count (216+/-80x10(9)/L, pre; 198+/-68, post; p=0.0001), and the higher the pre-dialysis platelet count, the greater the decrease (r=0.623, p=0.0001). Post-dialysis triglyceride decreased (1.67+/-1.27 mmol/L, pre; 1.23+/-0.96, post; p=0.0001). Tissue factor pathway inhibitor (TFPI) antigen plasma level was higher in uremic patients than in controls (114+/-42 ng/ml vs. 64+/-2, p= 0.0001). TFPI increased 2.3 times following dialysis and such an increase was directly correlated with post-dialysis plasma heparin concentration (r=0.571, p=0.0002) and inversely correlated with postdialysis triglyceride variation (r=0.407, p=0.005). Six of fifty patients (12%) had anti-heparin/platelet factor 4 antibodies (Hab), 3 IgG, and 3 IgM. Female sex and the use of cuprophane membranes were more frequent among Hab-positive patients (p=0.0001), while a lower percentage of them were on anti-aggregating drugs as compared to Hab-negative patients (p=0.002). Only one Hab-positive patient was slightly thrombocytopenic and none showed bleeding or thrombotic manifestations. Serum albumin and gamma globulin decreased following dialysis in Hab-positive patients, while the opposite was seen in those Hab-negative (-2.47+/-1.72 g/L, vs. 0.21+/-1.77, p=0.001 and -0.48+/-0.60 g/L vs. 0.64+/-0.97, p=0.007, respectively). In vivo factors other than Hab are involved in the development of heparin-induced thrombocytopenia. Besides a blunted immunological response, increased levels of TFPI, the use of anti-aggregating drugs, and the observed behavior of serum proteins might play a role in this regard. (C) 1998 Elsevier Science Ltd.
引用
收藏
页码:115 / 122
页数:8
相关论文
共 30 条
[1]  
AMIRAL J, 1992, THROMB HAEMOSTASIS, V68, P95
[2]  
AMIRAL J, 1995, THROMB HAEMOSTASIS, V73, P21
[3]  
Arepally G, 1995, AM J CLIN PATHOL, V104, P648
[4]   Heparin-induced thrombocytopenia: Understanding improves but questions remain [J].
Aster, RH .
JOURNAL OF LABORATORY AND CLINICAL MEDICINE, 1996, 127 (05) :418-419
[5]  
Bloom DMS, 1996, THROMB HAEMOSTASIS, V76, P480
[6]  
BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90
[7]   Tissue factor pathway inhibitor (TFPI) antigen plasma level in patients with interstitial lung disease before and after heparin administration [J].
Cella, G ;
Cipriani, A ;
Tommasini, A ;
Rampin, E ;
Sbarai, A ;
Rocconi, R ;
Mazzaro, G ;
Luzzatto, G .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1997, 23 (01) :45-49
[8]   Tissue factor pathway inhibitor (TFPI) activity in uremic patients during hemodialysis [J].
Cella, G ;
Vertolli, U ;
Naso, A ;
Vianello, A ;
Rampin, E ;
Sbarai, A ;
Boeri, G ;
Strauss, WE .
THROMBOSIS RESEARCH, 1996, 81 (06) :671-677
[9]  
deSancho M, 1996, THROMB HAEMOSTASIS, V75, P695
[10]  
DESCAMPSLATSCHA B, 1994, SEMIN NEPHROL, V14, P253